Clinical Data Arthrosi drug trial in gout delivers for new owner Sobi PharmaphorumSobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.Immunology & InflammationRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) Pharmaphorum Sobi’s $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad. Immunology & Inflammation Read full story Post navigation Previous: Lilly’s Verve gambit pays off as base editor cuts cholesterol in early studyNext: Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
